Camille L. Bedrosian's most recent trade in Amylyx Pharmaceuticals Inc was a trade of 143,985 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 5, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Amylyx Pharma Inc | Camille L. Bedrosian | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2026 | 143,985 | 143,985 | - | - | Stock Option (Right to Buy) | |
| Amylyx Pharma Inc | Camille L. Bedrosian | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2026 | 95,990 | 265,285 | - | 0 | Common Stock | |
| Amylyx Pharma Inc | Camille L. Bedrosian | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 14.35 per share. | 01 Dec 2025 | 6,580 | 175,756 | - | 14.3 | 94,418 | Common Stock |
| Amylyx Pharma Inc | Camille L. Bedrosian | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 14.58 per share. | 30 Sep 2025 | 12,039 | 182,336 | - | 14.6 | 175,518 | Common Stock |
| Rhythm Pharma Inc | Camille L. Bedrosian | Director | 24 Jun 2025 | 7,037 | 7,037 | - | - | Stock Option (right to buy) | ||
| Rhythm Pharma Inc | Camille L. Bedrosian | Director | 24 Jun 2025 | 4,712 | 4,712 | - | - | Restricted Stock Units | ||
| Rhythm Pharma Inc | Camille L. Bedrosian | Director | 18 Jun 2025 | 4,000 | 0 | - | - | Restricted Stock Units | ||
| Rhythm Pharma Inc | Camille L. Bedrosian | Director | 18 Jun 2025 | 4,000 | 7,000 (0%) | 0% | - | Common Stock | ||
| Crinetics Pharma Inc | Camille L. Bedrosian | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2025 | 10,350 | 10,350 | - | - | Stock Option (right to buy) | |
| Crinetics Pharma Inc | Camille L. Bedrosian | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2025 | 6,900 | 16,300 (0%) | 0% | 0 | Common Stock | |
| Amylyx Pharma Inc | Camille L. Bedrosian | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 3.47 per share. | 31 Mar 2025 | 12,425 | 194,375 | - | 3.5 | 43,082 | Common Stock |
| Amylyx Pharma Inc | Camille L. Bedrosian | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 102,630 | 102,630 | - | - | Stock Option (Right to Buy) | |
| Amylyx Pharma Inc | Camille L. Bedrosian | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 68,420 | 206,800 | - | 0 | Common Stock | |
| Amylyx Pharma Inc | L. Camille Bedrosian | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 5.54 per share. | 02 Dec 2024 | 5,421 | 138,380 | - | 5.5 | 30,007 | Common Stock |
| Amylyx Pharma Inc | Camille L. Bedrosian | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 3.20 per share. | 30 Sep 2024 | 11,442 | 143,801 | - | 3.2 | 36,559 | Common Stock |
| Rhythm Pharma Inc | Camille L. Bedrosian | Director | 21 Jun 2024 | 3,000 | 0 | - | - | Restricted Stock Units | ||
| Rhythm Pharma Inc | Camille L. Bedrosian | Director | 21 Jun 2024 | 3,000 | 3,000 (0%) | 0% | - | Common Stock | ||
| Rhythm Pharma Inc | Camille L. Bedrosian | Director | 18 Jun 2024 | 14,000 | 14,000 | - | - | Stock Option (right to buy) | ||
| Rhythm Pharma Inc | Camille L. Bedrosian | Director | 18 Jun 2024 | 4,000 | 4,000 | - | - | Restricted Stock Units | ||
| Crinetics Pharma Inc | Camille L. Bedrosian | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 12,500 | 12,500 | - | - | Stock Option (right to buy) | |
| Crinetics Pharma Inc | Camille L. Bedrosian | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 3,400 | 9,400 (0%) | 0% | 0 | Common Stock | |
| Amylyx Pharma Inc | Camille L. Bedrosian | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Apr 2024 | 120,000 | 120,000 | - | - | Stock Option (Right to Buy) | |
| Amylyx Pharma Inc | Camille L. Bedrosian | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Apr 2024 | 96,910 | 155,243 | - | 0 | Common Stock | |
| Amylyx Pharma Inc | Camille L. Bedrosian | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Nov 2023 | 162,500 | 162,500 | - | - | Stock Option (Right to Buy) | |
| Amylyx Pharma Inc | Camille L. Bedrosian | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Nov 2023 | 58,333 | 58,333 | - | 0 | Common Stock | |
| Rhythm Pharma Inc | Camille L. Bedrosian | Director | 21 Jun 2023 | 14,000 | 14,000 | - | - | Stock Option (right to buy) | ||
| Rhythm Pharma Inc | Camille L. Bedrosian | Director | 21 Jun 2023 | 3,000 | 3,000 | - | - | Restricted Stock Units | ||
| Crinetics Pharma Inc | Camille L. Bedrosian | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Crinetics Pharma Inc | Camille L. Bedrosian | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 6,000 | 6,000 (0%) | 0% | 0 | Common Stock | |
| Ultragenyx Pharmaceutical Inc | Camille L. Bedrosian | EVP and Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 45.25 per share. | 01 Mar 2023 | 3,881 | 46,720 (0%) | 0% | 45.2 | 175,615 | Common Stock |
| Ultragenyx Pharmaceutical Inc | Camille L. Bedrosian | EVP and Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 2,663 | 50,601 (0%) | 0% | 0 | Common Stock | |
| Crinetics Pharma Inc | Camille L. Bedrosian | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2022 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Rhythm Pharma Inc | Camille L. Bedrosian | Director | 08 Jun 2022 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | ||
| Ultragenyx Pharmaceutical Inc | Camille L. Bedrosian | EVP and Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 24,900 | 24,900 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical Inc | Camille L. Bedrosian | EVP and Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 14,000 | 47,938 (0%) | 0% | 0 | Common Stock | |
| Ultragenyx Pharmaceutical Inc | Camille L. Bedrosian | EVP and Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 66.62 per share. | 01 Mar 2022 | 2,821 | 33,938 (0%) | 0% | 66.6 | 187,935 | Common Stock |
| Ultragenyx Pharmaceutical Inc | Camille L. Bedrosian | EVP and Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 66.30 per share. | 30 Jan 2022 | 1,657 | 36,759 (0%) | 0% | 66.3 | 109,859 | Common Stock |
| Ultragenyx Pharmaceutical Inc | Camille L. Bedrosian | EVP and Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 81.14 per share. | 14 Oct 2021 | 359 | 38,416 (0%) | 0% | 81.1 | 29,129 | Common Stock |
| Ultragenyx Pharmaceutical Inc | Camille L. Bedrosian | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 55.00 per share. | 01 Sep 2021 | 2,500 | 41,275 (0%) | 0% | 55 | 137,500 | Common Stock |
| Ultragenyx Pharmaceutical Inc | Camille L. Bedrosian | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2021 | 2,500 | 53,000 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical Inc | Camille L. Bedrosian | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2021 | 2,500 | 55,500 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical Inc | Camille L. Bedrosian | EVP and Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 100.18 per share. | 01 Sep 2021 | 2,500 | 38,775 (0%) | 0% | 100.2 | 250,450 | Common Stock |
| Ultragenyx Pharmaceutical Inc | Camille L. Bedrosian | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 55.00 per share. | 01 Sep 2021 | 2,500 | 41,275 (0%) | 0% | 55 | 137,500 | Common Stock |
| Ultragenyx Pharmaceutical Inc | Camille L. Bedrosian | EVP and Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 100.03 per share. | 01 Sep 2021 | 2,500 | 38,775 (0%) | 0% | 100.0 | 250,075 | Common Stock |
| Crinetics Pharma Inc | Camille L. Bedrosian | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Rhythm Pharma Inc | Camille L. Bedrosian | Director | 09 Jun 2021 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | ||
| Ultragenyx Pharmaceutical Inc | Camille L. Bedrosian | EVP and Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 113.67 per share. | 06 May 2021 | 364 | 38,775 (0%) | 0% | 113.7 | 41,376 | Common Stock |